

BMJ Best Practice

Superior vena cava syndrome

Straight to the point of care



Last updated: Jul 18, 2023

Table of Contents

Overview	3
Summary	3
Definition	3
Theory	4
Epidemiology	4
Aetiology	4
Pathophysiology	5
Classification	5
Case history	6
Diagnosis	8
Approach	8
History and exam	9
Risk factors	11
Investigations	12
Differentials	14
Management	15
Approach	15
Treatment algorithm overview	16
Treatment algorithm	17
Primary prevention	25
Patient discussions	25
Follow up	26
Monitoring	26
Complications	26
Prognosis	26
Guidelines	27
Diagnostic guidelines	27
Treatment guidelines	27
References	28
Images	32
Disclaimer	37

Summary

Superior vena cava (SVC) syndrome is a clinical condition that occurs due to obstruction of the SVC.

The most common aetiology is malignancy; however, there has been an increase in benign causes due to more frequent use of intravascular devices.

Although rarely fatal, it may sometimes present as life-threatening upper airway obstruction.

A high index of suspicion is required to make the diagnosis in many cases.

Treatment and prognosis depend on underlying aetiology.

Definition

Superior vena cava (SVC) syndrome is a clinical condition that occurs as a result of obstruction of the SVC, leading to interrupted venous return from the head, thorax, and upper extremities to the right atrium. The increased venous pressure results in oedema of the head, neck, and arms, often with cyanosis, plethora, and distended subcutaneous vessels.^{[1] [2]} It can be caused by either intraluminal obstruction of the SVC or extrinsic compression.

Epidemiology

Malignant causes accounted for >90% of cases around 25 years ago, but there has been an increase in benign causes of superior vena cava (SVC) syndrome, reflecting increased use of intravascular devices such as catheters, pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronisation therapy.[7] SVC syndrome occurs in approximately 15,000 people in the US every year.[1] Malignancy causes 65% of cases, most commonly lung cancer and non-Hodgkin's lymphoma. Malignant causes of SVC syndrome are more frequent in middle-aged to older adult males, while benign causes are equally distributed across both sexes and more commonly seen in younger people. Infectious causes (especially syphilitic aortic aneurysm and tuberculosis) accounted for the majority of cases 50 years ago, but are now rare, especially in developed countries.[8]

Aetiology

A total of 65% to 70% of cases are due to malignancy.[1] [2] Lung cancer is the most common aetiology, with non-small cell lung cancer accounting for 50% of cases of malignant superior vena cava (SVC) syndrome and small cell lung cancer for 25% cases.[9] [10] [11] Overall, 2% to 5% of all patients with lung cancer go on to develop SVC syndrome, while 10% to 20% of patients with small cell lung cancer develop the condition. This is most probably related to the central growth of these tumours.[12] Most patients with lung cancer-associated SVC syndrome have right-sided lesions (80%). Lymphoma is the second most common cause, accounting for 12% of cases of malignant SVC syndrome; diffuse large cell lymphoma is the most common type (two-thirds), followed by lymphoblastic lymphoma (one third). Of patients with primary mediastinal B-cell lymphoma with sclerosis (a rare subtype of non-Hodgkin's lymphoma), the prevalence of SVC syndrome is high, with one study reporting 57%.[13] Although Hodgkin's lymphoma often involves the mediastinum, SVC syndrome is rare.[14] Thymoma (2%) and germ cell tumours (3%) are other primary mediastinal malignancies that occasionally cause SVC syndrome.[15]

The most common metastatic disease that causes SVC syndrome is breast cancer, accounting for 11% of cases.[6] Other metastatic tumours that cause SVC syndrome include colon cancer, oesophageal cancer, Kaposi's sarcoma, and fibrous mesothelioma.

Benign causes of SVC syndrome are less frequent (30%-35%).[1] [2] They include iatrogenic causes associated with SVC thrombosis (e.g., central venous catheters, pacemaker and implantable cardioverter-defibrillator leads), mediastinal fibrosis caused by radiotherapy or infections (e.g., histoplasmosis, tuberculosis, aspergillosis, blastomycosis, or nocardiosis), collagen-vascular diseases like sarcoidosis or Behcet's syndrome, and, rarely, aortic arch aneurysm, large substernal goitre, mediastinal haematoma as a result of trauma, and bicaval anastomotic stenosis following cardiac transplantation.[1] [11] [16]

Complications of pacemaker lead placement, such as venous thrombosis and stenosis, occur in up to 30% of patients, but only a few patients become symptomatic; however, the presence of multiple leads, retention of severed lead(s), and previous lead infection may increase risk of SVC syndrome.

In children, SVC syndrome is most often caused by non-Hodgkin's lymphoma. The compression of the SVC may be associated with compression of the trachea, which is narrow, flexible, and soft relative to that of an adult. This may result in airway obstruction in children.

Pathophysiology

The superior vena cava (SVC) extends from the junction of the right and left brachiocephalic veins to the right atrium. It drains venous blood from the head, neck, upper extremities, and upper thorax to the right atrium. It is located in the middle mediastinum and is surrounded by structures including the trachea, right bronchus, aorta, pulmonary artery, and the perihilar and paratracheal lymph nodes.

The thin-walled SVC can be obstructed by intraluminal, mural, or extrinsic factors. The extent and rapidity of obstruction correlates with elevation of venous pressure and symptomatic presentation. Slowly progressive obstruction leads to recruitment of collateral circulation via the azygos and internal mammary venous system (which takes several weeks).[17] With obstruction of the SVC, the cervical venous pressure is usually increased to 20 to 40 mmHg (normal range 2-8 mmHg).[18] When obstruction occurs abruptly, SVC syndrome can constitute a medical emergency.

An obstructed SVC initiates collateral venous return to the heart from the upper half of the body through four principal pathways. The most important pathway is the azygos venous system, which includes the azygos vein, the hemiazygos vein, and the connecting intercostal veins. The second pathway is the internal mammary venous system plus tributaries and secondary communications to the superior and inferior epigastric veins. The long thoracic venous system, with its connections to the femoral veins and vertebral veins, provides the third and fourth collateral routes, respectively.[1]

Classification


Classification based on location of superior vena cava (SVC) obstruction

Pre-azygos or supra-azygos

- Obstruction of blood return above the entrance of azygos vein into the SVC, resulting in venous distension and oedema of the face, neck, and upper extremities.[3] [4]

Post-azygos or infra-azygos

- Obstruction below the entrance of azygos vein into the SVC results in retrograde flow through the azygos via collaterals to the inferior vena cava, resulting in not only the symptoms and signs of pre-azygos disease, but also dilation of the veins over the abdomen.
- This is usually more severe and poorly tolerated than pre-azygos obstruction.



Supra- and infra-azygos obstruction leading to superior vena cava (SVC) syndrome. IVC: inferior vena cava

Reproduced with permission from Braunwald's Heart Disease, 8th ed (2008)

Classification based on aetiology of obstruction

- Luminal obstruction (e.g., pacemaker leads or catheter-related thrombosis).
- Extrinsic compression (e.g., malignancy, fibrosing mediastinitis due to infection/radiation, aortic arch aneurysm, haematoma, or goitre).

Case history

Case history #1

A 65-year-old man with a 40-year history of chronic smoking, hypertension, and chronic obstructive pulmonary disease presents with anorexia and weight loss for the past 6 months. He had been complaining of increased dyspnoea with exertion and orthopnoea, and has noticed bilateral arm swelling and facial plethora for the past 3 weeks. At the time of admission, his face and upper extremities were oedematous, and there were engorged veins in his neck and upper extremity.

Case history #2

A 70-year-old woman, with a history of ischaemic cardiomyopathy, left ventricular ejection fraction of 25%, and prior history of cardiac resynchronisation therapy 3 years ago, presents with slowly progressive swelling of the face and both arms, as well as prominent veins in the neck and upper extremities. She

gives a history of excessive bleeding from the site of venepuncture in the antecubital region after blood draws in the last few months.

Other presentations

Atypical presentations may include presentation to the emergency department with sudden-onset dyspnoea due to laryngeal oedema that can be acutely fatal due to upper airway compromise.^[5] In addition, cyanosis, papilloedema, cerebral oedema, mental changes, stupor, and even coma have been described with severe obstruction.^{[1] [6]}

Approach

The diagnosis of superior vena cava (SVC) syndrome is usually clinical and requires a high degree of suspicion; thus, a good history and physical examination are important. Chest CT/MRI is the initial test of choice required to confirm the diagnosis and to evaluate for underlying aetiology. Obtaining tissue for histopathology may be required in cases of suspected malignancy or infection.

History

History may also be notable for smoking, multiple pacemaker leads, or central venous catheters. Previous history of radiation exposure should be noted, as excess radiation to the mediastinum can lead to fibrosis causing SVC obstruction.

Early in the course, partial SVC obstruction may be asymptomatic or associated with subtle symptoms. With progressive obstruction, the classic symptoms and signs become more obvious. The most common symptoms are facial swelling, dyspnoea, cough, arm swelling, and facial plethora.^{[1] [2]} Sudden-onset dyspnoea due to laryngeal oedema can be fatal as a result of upper airway compromise.^[5] Other symptoms include headache, chest pain, blurred vision, hoarseness of voice, and stridor. Symptoms are usually worsened by bending forwards or lying down.

History of associated anorexia, weight loss, cough, dyspnoea, and haemoptysis may suggest lung malignancy (or possibly chronic infection). Fever, skin rash, or arthralgias may be indicative of underlying collagen-vascular diseases.

Physical examination

Examination usually reveals engorged veins of the neck and upper chest wall, facial oedema, and upper-extremity oedema. Prominent collateral veins covering the anterior chest wall may be visible. The manoeuvre of bending forwards usually worsens venous engorgement and is a helpful clinical sign. Laryngeal oedema, cyanosis, papilloedema, mental changes, stupor, and even coma have been described with severe obstruction.^{[1] [6]} When lymphadenopathy is present outside the chest, lymphoma should be considered a possibility.

Investigations

Chest x-ray may be performed as an initial test and sometimes reveals a widened mediastinum or mass lesion in the lung, but the most important radiological investigation when diagnosis is clinically suspected is chest CT (with intravenous contrast).^{[1] [2]} It establishes the diagnosis of SVC obstruction and shows the exact location, severity, and associated pathology (e.g., malignancy or intravascular thrombosis). MRI may also be useful but does not have any distinct advantages over CT, except in patients with contrast allergy or renal failure, as it avoids iodinated contrast.^{[1] [2]}

Ultrasound of the upper extremities is a useful non-invasive screening test and helps in identification of venous thrombosis or obstruction.^{[2] [19]} Presence of monophasic flow in the SVC or loss of respiratory variation on Doppler ultrasound can suggest SVC obstruction.

Bilateral upper-extremity venography can accurately delineate the site and extent of SVC obstruction and collateral pathways, but does not provide information about lung and mediastinal pathology. Venography is usually not required for diagnosis, but may be helpful to plan stent placement or surgery.^{[1] [2]}

Other investigations

Obtaining a tissue diagnosis is important to confirm the presence of malignancy. A biopsy from supraclavicular or other cervical lymph nodes may obviate the need for invasive procedures like mediastinoscopy, and thus careful examination for cervical lymphadenopathy should be performed. For diagnosis of malignancy, bronchoscopy has a diagnostic yield of 50% to 70%, transthoracic needle-aspiration biopsy has a yield of approximately 75%, and mediastinoscopy or mediastinotomy has a diagnostic yield of >90%.^[1]

Sputum examination for culture, acid-fast staining, and cytology is helpful in diagnosis of cases with tuberculosis, fungal infections (e.g., aspergillosis, blastomycosis, histoplasmosis, nocardiosis), or endobronchial malignancy. Thoracentesis with cytological analysis should be strongly considered whenever pleural effusion is present.

Erythrocyte sedimentation rate or C-reactive protein may be elevated in patients with infection or immunological disorders.

History and exam

Key diagnostic factors

presence of risk factors (common)

- Key risk factors include smoking history, multiple pacemaker leads, and central venous catheters.

localised oedema of the face and upper extremities (common)

- Present in 80% of cases.^[9]
- If oedema is localised to upper extremities and face, obstruction of the superior vena cava should be considered.

dyspnoea (common)

- Present in 60% of cases.^[20]
- Usually made worse by bending forwards or lying down (orthopnoea).
- May suggest lung malignancy or chronic infection.

facial plethora (common)

- Due to venous engorgement and oedema.

cough (common)

- Present in 54% of cases.^[10]
- Can be related to underlying aetiology or laryngeal oedema.

distended neck veins (common)

- Seen in 63% of cases and due to increased venous pressure.^[1]
- Bending forwards usually worsens venous engorgement and is a helpful clinical sign.

distended chest veins (common)

- Seen in 53% of cases and due to increased venous pressure.[1]
- Prominent collateral veins covering the anterior chest wall may be visible.
- Bending forwards usually worsens venous engorgement and is a helpful clinical sign.

hoarseness of voice (common)

- Present in 17% of cases.[6]
- Can be related to underlying aetiology or laryngeal oedema.

lymphadenopathy (common)

- Lymphoma is a possibility if lymphadenopathy is outside of the chest.

blurred vision (uncommon)

- Present in 2% of cases.[6]

stridor (uncommon)

- Present in 4% of cases.[6]
- Related to laryngeal oedema or direct compression.

confusion/stupor (uncommon)

- Present in 4% of cases and due to cerebral oedema.
- Has been described with severe obstruction.[1] [6]

Other diagnostic factors**anorexia (common)**

- May suggest lung malignancy or chronic infection.

weight loss (common)

- May suggest lung malignancy or chronic infection.

haemoptysis (common)

- May suggest lung malignancy or chronic infection.

headache (uncommon)

- Present in 9% of cases.[6]
- Due to increased cerebral venous pressure.

chest pain (uncommon)

- Usually pleuritic; related to pleural involvement from malignancy, infection, or autoimmune diseases.

mental changes (uncommon)

- Has been described with severe obstruction.[1] [6]

fever (uncommon)

- May be indicative of collagen-vascular disease.

skin rash (uncommon)

- May be indicative of collagen-vascular disease.

arthralgia (uncommon)

- May be indicative of collagen-vascular disease.

laryngeal oedema (uncommon)

- Has been described with severe obstruction.[\[1\]](#) [\[6\]](#)

cyanosis (uncommon)

- Has been described with severe obstruction.[\[1\]](#) [\[6\]](#)

papilloedema (uncommon)

- Has been described with severe obstruction.[\[1\]](#) [\[6\]](#)

coma (uncommon)

- Has been described with severe obstruction.[\[1\]](#) [\[6\]](#)

Risk factors

Strong**smoking**

- Strong relationship to lung cancer, the most common overall cause of superior vena cava syndrome.

multiple pacemaker leads

- Becoming an increasingly frequent benign cause of superior vena cava syndrome.

central venous catheters/ports

- Becoming an increasingly frequent benign cause of superior vena cava syndrome.[\[8\]](#)

Weak**age >50 years**

- Lung malignancy should be considered as the most likely aetiology in patients >50 years of age.

radiation

- Excess radiation to the mediastinum can lead to fibrosis causing superior vena cava obstruction.

Investigations

1st test to order

Test	Result
chest x-ray <ul style="list-style-type: none"> Ordered when superior vena cava syndrome is clinically suspected, especially with a history of pulmonary symptoms. 	widened mediastinum or mass lesion in the lung
chest CT <ul style="list-style-type: none"> Most useful imaging test as it helps to establish diagnosis.^{[1] [2]} Undertaken with intravenous contrast. Ordered when there is clinical suspicion of superior vena cava syndrome. Helpful in obtaining a tissue diagnosis by CT-guided biopsy. 	full or partial obstruction; development of collateral vessels; shows location, severity, and associated pathology (e.g., malignancy or intravascular thrombosis)
chest MRI <ul style="list-style-type: none"> Useful in patients with a history of contrast allergy or those at risk of contrast-induced worsening of renal function.^{[1] [2]} Caution advised in use of gadolinium in renal insufficiency due to risk of nephrogenic fibrosing dermopathy. Contraindicated in patients with pacemakers and defibrillators. 	full or partial obstruction; development of collateral vessels; shows location, severity, and associated pathology (e.g., malignancy or intravascular thrombosis)
ultrasound of upper extremities <ul style="list-style-type: none"> Useful non-invasive screening test. Helps in identification of venous thrombosis or obstruction.^{[2] [19]} Presence of monophasic flow in the superior vena cava (SVC) or loss of respiratory variation on Doppler ultrasound can suggest SVC obstruction. 	dilated SVC; presence of thrombus; monophasic flow; loss of respiratory variation

Other tests to consider

Test	Result
venography <ul style="list-style-type: none"> Invasive test, usually performed by venous catheterisation through the femoral vein and injection of contrast dye in the superior vena cava (SVC). Does not provide information about lung or mediastinal pathology.[1] Not usually required for diagnosis, but may be useful for planning endoscopic interventions or before surgery.[1] [2] 	defines site and extent of SVC obstruction and collateral pathways
biopsy <ul style="list-style-type: none"> Obtaining tissue diagnosis is important to confirm presence of malignancy. Bronchoscopy has a diagnostic yield of 50% to 70%, transthoracic needle-aspiration biopsy has a yield of approximately 75%, and mediastinoscopy or mediastinotomy has a diagnostic yield of >90%.[1] Biopsy from supraclavicular or other cervical lymph node may obviate the need for invasive procedures such as mediastinoscopy and, thus, careful examination for cervical lymphadenopathy should be performed. 	specimen for pathological diagnosis
sputum cytology <ul style="list-style-type: none"> Simple, non-invasive method to detect lung malignancy. More likely to be positive with central lesions than with peripheral lesions. Thoracentesis with cytological analysis should be strongly considered when pleural effusion is present. 	malignant cells in sputum
thoracentesis <ul style="list-style-type: none"> Thoracentesis involves placing a needle between the ribs and into the chest to sample fluid that has accumulated in the pleural space. Thoracentesis with cytological analysis should be strongly considered whenever pleural effusion is present. 	malignant cells in pleural fluid
sputum culture <ul style="list-style-type: none"> Sputum examination for culture is helpful in diagnosis of cases with tuberculosis, or bacterial or fungal infections (e.g., aspergillosis, blastomycosis, histoplasmosis, nocardiosis). 	growth of specific organisms
erythrocyte sedimentation rate <ul style="list-style-type: none"> May be present in patients with infection or immunological disorders. 	elevated
C-reactive protein <ul style="list-style-type: none"> May be present in patients with infection or immunological disorders. 	elevated

Differentials

Condition	Differentiating signs / symptoms	Differentiating tests
Cardiac tamponade	<ul style="list-style-type: none"> • Absence of facial and upper-extremity oedema. • Variation of jugular venous pressure with respiration (prominent x-descent). • Pulsus paradoxus present. 	<ul style="list-style-type: none"> • Pericardial effusion is seen on CT chest. • Echocardiography shows bouncing septum, marked respiratory variation in the early left ventricular filling velocity (>25%), and right ventricular diastolic collapse.
Constrictive pericarditis	<ul style="list-style-type: none"> • Elevated jugular venous pressure (JVP) with prominent negative descents (x- and y-descent). • Presence of Kussmaul's sign (increase in JVP with inspiration). 	<ul style="list-style-type: none"> • Echocardiography may show thickened pericardium and marked respiratory variation in the early left ventricular filling velocity (>25%). • MRI is the investigation of choice, as it shows pericardial thickening and ventricular interdependence. • Cardiac catheterisation shows discordance of left and right ventricular pressures with respiration, which has high specificity for diagnosis.
Acute COPD exacerbation	<ul style="list-style-type: none"> • Extensive bilateral expiratory wheezing, hypoxia, and hypercarbia. 	<ul style="list-style-type: none"> • Peak flow, spirometry, and bronchodilator response help in differentiating. • Presence of obstructive defect on pulmonary function testing is seen.
Right-sided heart failure	<ul style="list-style-type: none"> • Preserved respiratory variation in jugular venous pressure, prominent negative descents, and sometimes increased v wave due to tricuspid regurgitation. 	<ul style="list-style-type: none"> • Echocardiography will show right ventricular dysfunction and dilated inferior vena cava with lack of inspiratory collapse.
Pulmonary embolism	<ul style="list-style-type: none"> • Upper-extremity oedema is usually absent. 	<ul style="list-style-type: none"> • CT chest with contrast will show presence of thrombus inside the pulmonary artery.
Cardiac tumour	<ul style="list-style-type: none"> • Upper-extremity oedema is usually absent. 	<ul style="list-style-type: none"> • Echocardiography or cardiac MRI will show presence of a mass, usually inside the right side of the heart.

Approach

Once diagnosis has been established, a malignant or non-malignant cause of superior vena cava (SVC) syndrome must be determined, as treatment options differ. Treatment involves relieving the symptoms of obstruction and treating the underlying aetiology. There have been no large randomised trials to compare various treatment options, and most data are from case series and expert opinion. Treatment of SVC syndrome is inter-disciplinary and may involve oncology, respiratory, surgery, radiology, vascular, and endovascular specialists.[2]

Acute airway obstruction (without tissue diagnosis)

Presentation with airway obstruction is serious, although rare in current clinical practice. First-line treatment consists of securing the airway and relief of obstructive symptoms. This can be achieved with either a combination of corticosteroids and radiotherapy, or percutaneous stenting.[2] Urgent treatment with radiotherapy and corticosteroids should be used only for life-threatening situations. It should be deferred otherwise, due to interference with subsequent histopathological diagnosis. Stenting is increasingly used because the stent can be placed before a tissue diagnosis is available. It is a useful procedure for patients with severe symptoms such as respiratory distress that require urgent intervention.[21] [22] Meta-analyses have demonstrated that endovascular therapy with stenting has high technical and clinical success rates.[23] [24] [25]

In the absence of a need for urgent intervention, the management should focus initially on establishing the correct diagnosis.

Malignant obstructions

Malignant causes require further treatment with appropriate chemotherapy, radiation, and/or surgery. Most malignant tumours causing SVC syndrome are sensitive to radiotherapy. Chemotherapy is an effective option for treatment of lung cancer, lymphomas, and germ cell tumours.[26] Thymomas resistant to chemotherapy and radiation may require surgical resection and SVC reconstruction.[27] Selection of therapy will depend on the type of malignancy, staging, and histopathology. See Small cell lung cancer , Non-small cell lung cancer , Non-Hodgkin's lymphoma , Thymic tumour .

Endovascular stenting is performed to achieve more rapid improvement in symptoms and has fewer side effects compared with radiotherapy.[23] [24] [25]

Second-line treatment is palliative therapy. This includes palliative radiotherapy, chemotherapy or corticosteroids (for lymphomas and thymomas), endovascular stents, or rarely bypass surgery.[1] [2] In rare cases, surgical decompression can be performed. Thrombolysis with indwelling catheters has also been described in small studies.[28] Supportive treatment consists of diuretics, low-salt diet, avoidance of upper-extremity lines, head elevation, and oxygen.

Benign obstructions

Benign causes can be managed with percutaneous stenting, intravascular thrombolysis, bypass grafting, anticoagulation, or treatment of underlying infectious aetiology.

Underlying infection (e.g., aspergillosis, blastomycosis, histoplasmosis, nocardiosis) should be treated according to local sensitivities. Endovascular stents and more rarely bypass surgery may be required if SVC obstruction persists after treatment of infection.

Catheter(s) should be removed and local thrombolysis and/or short-course anticoagulation should be considered in patients with thrombosis due to central venous catheter(s).^[29]

Percutaneous balloon dilatation/stenting is preferred in patients with pacemaker and implantable cardioverter-defibrillator lead-related venous occlusion. Lead explantation may carry a high risk of mortality.^[30] Bypass surgery may be an option. Infection of the leads should always be considered as a possibility and evaluated with blood cultures and transoesophageal echocardiogram. Anticoagulation with warfarin should be considered. Data regarding post-procedural anticoagulation are lacking, and practices vary.^[2]

Treatment algorithm overview

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: [see disclaimer](#)

Acute (summary)		
acute airway obstruction (without tissue diagnosis)		
	1st	secure airway + radiotherapy + corticosteroids
	1st	secure airway + percutaneous endovascular stenting
Ongoing (summary)		
malignant aetiology		
	1st	treatment of malignancy
	plus	percutaneous endovascular stenting
	2nd	palliative therapy
infectious aetiology		
	1st	treatment of infection
	2nd	palliative therapy
iatrogenic aetiology		
■ thrombosis due to central venous catheter(s)	1st	catheter removal + thrombolysis and/or anticoagulation
■ pacemaker and implantable cardioverter-defibrillator lead-related venous occlusion	1st	percutaneous balloon dilatation/stenting with or without lead removal

Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: [see disclaimer](#)

Acute

acute airway obstruction (without tissue diagnosis)

- | | |
|------------|---|
| 1st | secure airway + radiotherapy + corticosteroids

Primary options

» dexamethasone : 10 mg intravenous bolus initially, followed by 4 mg every 6 hours

» Airway should be secured by intubation or surgically first.

» Urgent treatment with radiotherapy and corticosteroids should be used only for life-threatening situations. It should be deferred otherwise, due to interference with subsequent histopathological diagnosis.

» Dose of corticosteroids should be limited and the dose decreased after 1 to 2 days of treatment or following symptomatic improvement. |
| 1st | secure airway + percutaneous endovascular stenting

» Airway should be secured by intubation or surgically first.

» Becoming increasingly used, because the stent can be placed before a tissue diagnosis is available. It is a useful procedure for patients with severe symptoms such as respiratory distress that require urgent intervention. ^[21] ^[22] Meta-analyses have demonstrated that endovascular therapy with stenting has high technical and clinical success rates. ^[23] ^[24] ^[25]

» Done percutaneously by obtaining access usually through the femoral vein. Performed under conscious sedation. Fluoroscopic guidance and iodinated contrast are used. Most operators use heparin during the procedure. |

Acute

Post-dilatation of the superior vena cava stent

Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission




Venography showing superior vena cava stenosis. Stent placement in the left pulmonary artery is seen

Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission

Acute

*Percutaneous balloon angioplasty of the stenotic lesion in superior vena cava
Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission*



*Stent deployment in the superior vena cava
Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission*

- » Self-expanding or balloon-expandable stents may be used (usually bare metal stents).
- » Complications of percutaneous stenting are in the range of 3% to 7% and include volume overload due to sudden increase in preload, stent thrombosis, pulmonary embolus, stent migration, haematoma at the insertion site,

Acute

infection, bleeding, and, very rarely, perforation or death.[\[22\]](#)

» Patency rate is around 80% to 94%, and 20% of patients may require repeat stenting.

» Bleeding risk is 1% to 14%, due to anticoagulation with aspirin, clopidogrel, and/or warfarin, which may be used following stent placement to prevent thrombosis.[\[21\]](#) [\[31\]](#)

» Data regarding post-procedural anticoagulation are lacking, and practices vary.[\[2\]](#)

Ongoing

malignant aetiology

1st treatment of malignancy

- » Most malignant tumours causing superior vena cava (SVC) syndrome are sensitive to radiotherapy.
- » Chemotherapy is an effective option for treatment of lung cancer, lymphomas, and germ cell tumours.[26]
- » Thymomas that are resistant to chemotherapy and radiation may require surgical resection and SVC reconstruction (operative mortality rate of 5% and patency rate of 80% to 90%).[27]
- » Selection of therapy will depend on the type of malignancy, staging, and histopathology. See Small cell lung cancer , Non-small cell lung cancer , Non-Hodgkin's lymphoma , Thymic tumour .

plus percutaneous endovascular stenting


Treatment recommended for ALL patients in selected patient group

- » Endovascular stenting is performed to achieve more rapid improvement in symptoms and has fewer side effects compared with radiotherapy.[23] [24] [25]
- » Undertaken percutaneously by obtaining access (usually) through the femoral vein. Performed under conscious sedation. Fluoroscopic guidance and iodinated contrast are used and most operators use heparin during the procedure.



*Post-dilatation of the superior vena cava stent
Image obtained from cardiac catheterisation
laboratory at University of Missouri,
Columbia; used with permission*

Ongoing




*Venography showing superior vena cava stenosis. Stent placement in the left pulmonary artery is seen
Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission*



*Percutaneous balloon angioplasty of the stenotic lesion in superior vena cava
Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission*

Ongoing



*Stent deployment in the superior vena cava
Image obtained from cardiac catheterisation
laboratory at University of Missouri,
Columbia; used with permission*

- » Self-expanding or balloon-expandable stents may be used (usually bare metal stents).
- » Complications of percutaneous stenting are in the range of 3% to 7% and include volume overload due to sudden increase in preload, stent thrombosis, pulmonary embolus, stent migration, haematoma at the insertion site, infection, bleeding, and, very rarely, perforation or death.[22]
- » Patency rate is around 80% to 94%, and 20% of patients may require repeat stenting.
- » Bleeding risk is 1% to 14%, due to anticoagulation with aspirin, clopidogrel, and/or warfarin, which may be used following stent placement to prevent thrombosis.[21] [31]
- » Data regarding post-procedural anticoagulation are lacking, and practices vary.[2]

2nd

palliative therapy

- » Includes palliative radiotherapy, chemotherapy or corticosteroids (for lymphomas and thymomas), endovascular stents, or rarely bypass surgery, as it is invasive and difficult.[1]
- » In rare cases, surgical decompression can be performed.
- » Thrombolysis with indwelling catheters has also been described in small studies.[28]

Ongoing

» Supportive treatment consists of diuretics, low-salt diet, avoidance of upper-extremity lines, head elevation, and oxygen.

» Type of diuretic will depend on several factors including renal function and current or past history of diuretic use.

infectious aetiology

1st treatment of infection

» Underlying infection (e.g., aspergillosis, blastomycosis, histoplasmosis, nocardiosis) should be treated according to local sensitivities.

» Choice of antimicrobial will depend on the underlying pathogen.

2nd palliative therapy

» Endovascular stents and more rarely bypass surgery may be required if superior vena cava obstruction persists after treatment of infection.

iatrogenic aetiology

■ thrombosis due to central venous catheter(s)

1st catheter removal + thrombolysis and/or anticoagulation

» Catheter(s) should be removed and local thrombolysis and/or short-course anticoagulation should be considered in these patients.[29]

» Chronic warfarin therapy up to 1 year has been described in some reports.[32] Dose should be titrated to target INR of 2.0 to 3.0.

» Thrombolysis has higher success rates if used within first 5 days of development of superior vena cava obstruction.[28]

■ pacemaker and implantable cardioverter-defibrillator lead-related venous occlusion

1st percutaneous balloon dilatation/stenting with or without lead removal

» Percutaneous balloon dilatation/stenting is preferred in these patients.

» Lead explantation may carry a high risk of mortality (1% to 3%).[30] Bypass surgery may be an option.

» Infection of the leads should always be considered as a possibility and evaluated with blood cultures and transoesophageal echocardiogram.

» Long-term anticoagulation with warfarin should be considered. Dose should be titrated to target INR of 2.0 to 3.0.

Primary prevention

The most important primary prevention measure is to avoid smoking, which increases the risk of malignant causes of superior vena cava syndrome.

Patient discussions

Patients should be advised to monitor for symptoms of recurrence, such as upper-extremity swelling, engorged neck veins, facial oedema, or plethora. They should also be advised to report to the accident and emergency department if they develop dyspnoea or confusion.

Monitoring

Monitoring

Patients should be followed up regularly by their treating physician (i.e., oncologist/ surgeon/cardiologist/ radiotherapist). The duration, frequency of follow-up, and further workup generally depend on the underlying aetiology.

Complications

Complications	Timeframe	Likelihood
percutaneous stenting procedural complications	short term	low
<p>Procedural complications can include stent thrombosis or migration, dissection, perforation, bleeding, infection, or cardiac tamponade.</p> <p>May require percutaneous or surgical intervention.</p> <p>There is a risk of volume overload or heart failure exacerbation immediately following revascularisation due to sudden increase in venous return.</p>		
thrombolysis/anticoagulation-related bleeding	variable	low
<p>Minor or major bleeding complications can be related to systemic anticoagulation. They might necessitate holding the anticoagulant regimen, or possibly giving an antidote.</p>		

Prognosis

Prognosis usually depends on the underlying aetiology, with poorer prognosis for malignant conditions.

Malignant aetiology

In patients with treatment-responsive malignancies, superior vena cava (SVC) syndrome does not necessarily signify adverse outcomes. However, in patients with non-small cell lung cancer resistant to chemotherapy and radiotherapy, development of SVC syndrome is associated with poor prognosis and median survival of <6 months.^[33]

Benign aetiology

Patients treated for benign causes with stenting or surgery have patency rates of around 90%, though there may be a need for recurrent stenting in some cases. Following percutaneous stenting, patients may need to be on antiplatelet therapy or warfarin for 1 to 3 months, although there are no clear guidelines regarding the duration of treatment.^[22]

Diagnostic guidelines

North America

ACR Appropriateness Criteria: suspected upper-extremity deep vein thrombosis (<https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria>)

Published by: American College of Radiology

Last published: 2019

Treatment guidelines

United Kingdom

Guidance on use of vena cava filters (http://www.b-s-h.org.uk/guidelines/?category=Haemostasis+and+Thrombosis&p=1&search=#guideline-filters__select__status)

Published by: British Committee for Standards on Haematology

Last published: 2006

Stent placement for vena caval obstruction (<https://www.nice.org.uk/guidance/IPG79>)

Published by: National Institute for Health and Care Excellence

Last published: 2004

Europe

Quality assurance guidelines for superior vena cava stenting in malignant disease (<https://link.springer.com/article/10.1007/s00270-005-0284-9>)

Published by: Cardiovascular and Interventional Radiological Society of Europe **Last published:** 2015

North America

Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report (<https://www.chestnet.org/Guidelines-and-Resources>)

Published by: American College of Chest Physicians

Last published: 2016

Key articles

- Azizi AH, Shafi I, Shah N, et al. Superior vena cava syndrome. JACC Cardiovasc Interv. 2020 Dec 28;13(24):2896-2910. [Full text \(https://www.sciencedirect.com/science/article/pii/S1936879820319725?via%3Dihub\)](https://www.sciencedirect.com/science/article/pii/S1936879820319725?via%3Dihub) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/33357528?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/33357528?tool=bestpractice.bmj.com)
- American College of Radiology. ACR appropriateness criteria: suspected upper-extremity deep vein thrombosis. 2019 [internet publication]. [Full text \(https://acsearch.acr.org/docs/69417/Narrative\)](https://acsearch.acr.org/docs/69417/Narrative)
- Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):319-22. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16502166?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16502166?tool=bestpractice.bmj.com)
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52. [Full text \(http://journal.chestnet.org/article/S0012-3692\(15\)00335-9/fulltext\)](http://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.bmj.com)

References

1. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice: superior vena cava syndrome with malignant causes. N Engl J Med. 2007 May 3;356(18):1862-9. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/17476012?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/17476012?tool=bestpractice.bmj.com)
2. Azizi AH, Shafi I, Shah N, et al. Superior vena cava syndrome. JACC Cardiovasc Interv. 2020 Dec 28;13(24):2896-2910. [Full text \(https://www.sciencedirect.com/science/article/pii/S1936879820319725?via%3Dihub\)](https://www.sciencedirect.com/science/article/pii/S1936879820319725?via%3Dihub) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/33357528?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/33357528?tool=bestpractice.bmj.com)
3. Kim HJ, Kim HS, Chung SH. CT diagnosis of superior vena cava syndrome: importance of collateral vessels. AJR Am J Roentgenol. 1993;161:539-542. [Full text \(http://www.ajronline.org/doi/pdf/10.2214/ajr.161.3.8352099\)](http://www.ajronline.org/doi/pdf/10.2214/ajr.161.3.8352099) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8352099?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8352099?tool=bestpractice.bmj.com)
4. Stanford W, Jolles H, Ell S, et al. Superior vena cava obstruction: a venographic classification. AJR Am J Roentgenol. 1987;148:259-262. [Full text \(http://www.ajronline.org/doi/pdf/10.2214/ajr.148.2.259\)](http://www.ajronline.org/doi/pdf/10.2214/ajr.148.2.259) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/3492099?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/3492099?tool=bestpractice.bmj.com)
5. Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984;2:961-969. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/6205125?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/6205125?tool=bestpractice.bmj.com)

6. Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. *Am J Surg.* 1990;160:207-211. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/2382775?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/2382775?tool=bestpractice.bmj.com)
7. Schechter MM. The superior vena cava syndrome. *Am J Med Sci.* 1954;227:46-56. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/13114214?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/13114214?tool=bestpractice.bmj.com)
8. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. *Medicine (Baltimore).* 2006;85:37-42. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16523051?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16523051?tool=bestpractice.bmj.com)
9. Armstrong BA, Perez CA, Simpson JR, et al. Role of irradiation in the management of superior vena cava syndrome. *Int J Radiat Oncol Biol Phys.* 1987;13:531-539. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/3558044?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/3558044?tool=bestpractice.bmj.com)
10. Yellin A, Rosen A, Reichert N, et al. Superior vena cava syndrome: the myth - the facts. *Am Rev Respir Dis.* 1990;141:1114-1118. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/2339833?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/2339833?tool=bestpractice.bmj.com)
11. Parish JM, Marschke RF Jr, Dines DE, et al. Etiologic considerations in superior vena cava syndrome. *Mayo Clin Proc.* 1981;56:407-413. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/7253702?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/7253702?tool=bestpractice.bmj.com)
12. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. *Arch Intern Med.* 1993;153:384-387. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8381263?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8381263?tool=bestpractice.bmj.com)
13. Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. *J Clin Oncol.* 1993 Dec;11(12):2306-13. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8246020?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8246020?tool=bestpractice.bmj.com)
14. Presswala RG, Hiranandani NL. Pleural effusion and superior vena cava canal syndrome in Hodgkin's disease. *J Indian Med Assoc.* 1965;45:502-503. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/5838468?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/5838468?tool=bestpractice.bmj.com)
15. Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. *Springerplus.* 2016;5:229. [Full text \(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771672\)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771672) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/27026923?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/27026923?tool=bestpractice.bmj.com)
16. Schowengerdt CG, Suyemoto R, Main FB. Granulomatous and fibrous mediastinitis. A review and analysis of 180 cases. *J Thorac Cardiovasc Surg.* 1969;57:365-379. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/5773205?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/5773205?tool=bestpractice.bmj.com)
17. Trigaux JP, Van Beers B. Thoracic collateral venous channels: normal and pathologic CT findings. *J Comput Assist Tomogr.* 1990;14:769-773. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/2204637?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/2204637?tool=bestpractice.bmj.com)

18. Gonzalez-Fajardo JA, Garcia-Yuste M, Florez S, et al. Hemodynamic and cerebral repercussions arising from surgical interruption of the superior vena cava: experimental model. *J Thorac Cardiovasc Surg.* 1994;107:1044-1049. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8159025?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8159025?tool=bestpractice.bmj.com)
19. American College of Radiology. ACR appropriateness criteria: suspected upper-extremity deep vein thrombosis. 2019 [internet publication]. [Full text \(https://acsearch.acr.org/docs/69417/Narrative\)](https://acsearch.acr.org/docs/69417/Narrative)
20. Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruction: is it a medical emergency? *Am J Med.* 1981;70:1169-1174. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/7234887?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/7234887?tool=bestpractice.bmj.com)
21. Urruticoechea A, Mesia R, Dominguez J, et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion: experience on 52 patients with lung cancer. *Lung Cancer.* 2004;43:209-214. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/14739042?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/14739042?tool=bestpractice.bmj.com)
22. Schifferdecker B, Shaw JA, Piemonte TC, et al. Nonmalignant superior vena cava syndrome: pathophysiology and management. *Catheter Cardiovasc Interv.* 2005;65:416-423. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15926179?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15926179?tool=bestpractice.bmj.com)
23. Azizi AH, Shafi I, Zhao M, et al. Endovascular therapy for superior vena cava syndrome: A systematic review and meta-analysis. *EClinicalMedicine.* 2021 Jul;37:100970. [Full text \(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343254\)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343254) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/34386747?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/34386747?tool=bestpractice.bmj.com)
24. Aung EY, Khan M, Williams N, et al. Endovascular stenting in superior vena cava syndrome: a systematic review and meta-analysis. *Cardiovasc Intervent Radiol.* 2022 Sep;45(9):1236-54. [Full text \(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458578\)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458578) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/35821122?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/35821122?tool=bestpractice.bmj.com)
25. Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. *Cardiovasc Intervent Radiol.* 2006 May-Jun;29(3):319-22. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16502166?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16502166?tool=bestpractice.bmj.com)
26. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. *Clin Oncol (R Coll Radiol).* 2002;14:338-351. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12555872?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12555872?tool=bestpractice.bmj.com)
27. Detterbeck FC, Parsons AM. Thymic tumors. *Ann Thorac Surg.* 2004;77:1860-1869. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15111216?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15111216?tool=bestpractice.bmj.com)
28. Gray BH, Olin JW, Graor RA, et al. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. *Chest.* 1991;99:54-59. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/1984986?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/1984986?tool=bestpractice.bmj.com)
29. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest.* 2016 Feb;149(2):315-52. [Full text \(http://journal.chestnet.org/\)](http://journal.chestnet.org/)

- article/S0012-3692(15)00335-9/fulltext) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.bmj.com>)
-
30. Smith CW, Messenger JC, Schaner SP, et al. Cardiac pacemaker electrodes: improved methods of extraction. *Radiology*. 1994;193:739-742. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/7972816?tool=bestpractice.bmj.com>)
-
31. Courtheoux P, Alkofer B, Al Refai M, et al. Stent placement in superior vena cava syndrome. *Ann Thorac Surg*. 2003;75:158-161. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/12537210?tool=bestpractice.bmj.com>)
-
32. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. *Radiology*. 1998;206:187-193. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/9423671?tool=bestpractice.bmj.com>)
-
33. Martins SJ, Pereira JR. Clinical factors and prognosis in non-small cell lung cancer. *Am J Clin Oncol*. 1999;22:453-457. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/10521057?tool=bestpractice.bmj.com>)
-

Images




Figure 1: Supra- and infra-azygos obstruction leading to superior vena cava (SVC) syndrome. IVC: inferior vena cava

Reproduced with permission from Braunwald's Heart Disease, 8th ed (2008)




Figure 2: Post-dilatation of the superior vena cava stent

Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission




Figure 3: Venography showing superior vena cava stenosis. Stent placement in the left pulmonary artery is seen

Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission



Figure 4: Percutaneous balloon angioplasty of the stenotic lesion in superior vena cava

Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission




Figure 5: Stent deployment in the superior vena cava

Image obtained from cardiac catheterisation laboratory at University of Missouri, Columbia; used with permission

Disclaimer

BMJ Best Practice is intended for licensed medical professionals. BMJ Publishing Group Ltd (BMJ) does not advocate or endorse the use of any drug or therapy contained within this publication nor does it diagnose patients. As a medical professional you retain full responsibility for the care and treatment of your patients and you should use your own clinical judgement and expertise when using this product.

This content is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition, since such standards and practices in medicine change as new data become available, you should consult a variety of sources. We strongly recommend that you independently verify specified diagnosis, treatments and follow-up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the drug to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region.

Information included in BMJ Best Practice is provided on an “as is” basis without any representations, conditions or warranties that it is accurate and up to date. BMJ and its licensors and licensees assume no responsibility for any aspect of treatment administered to any patients with the aid of this information. To the fullest extent permitted by law, BMJ and its licensors and licensees shall not incur any liability, including without limitation, liability for damages, arising from the content. All conditions, warranties and other terms which might otherwise be implied by the law including, without limitation, the warranties of satisfactory quality, fitness for a particular purpose, use of reasonable care and skill and non-infringement of proprietary rights are excluded.

Where BMJ Best Practice has been translated into a language other than English, BMJ does not warrant the accuracy and reliability of the translations or the content provided by third parties (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages). BMJ is not responsible for any errors and omissions arising from translation and adaptation or otherwise. Where BMJ Best Practice lists drug names, it does so by recommended International Nonproprietary Names (rINNs) only. It is possible that certain drug formularies might refer to the same drugs using different names.

Please note that recommended formulations and doses may differ between drug databases drug names and brands, drug formularies, or locations. A local drug formulary should always be consulted for full prescribing information.

Treatment recommendations in BMJ Best Practice are specific to patient groups. Care is advised when selecting the integrated drug formulary as some treatment recommendations are for adults only, and external links to a paediatric formulary do not necessarily advocate use in children (and vice-versa). Always check that you have selected the correct drug formulary for your patient.

Where your version of BMJ Best Practice does not integrate with a local drug formulary, you should consult a local pharmaceutical database for comprehensive drug information including contraindications, drug interactions, and alternative dosing before prescribing.

Interpretation of numbers

Regardless of the language in which the content is displayed, numerals are displayed according to the original English-language numerical separator standard. For example 4 digit numbers shall not include a comma nor a decimal point; numbers of 5 or more digits shall include commas; and numbers stated to be less than 1 shall be depicted using decimal points. See Figure 1 below for an explanatory table.

BMJ accepts no responsibility for misinterpretation of numbers which comply with this stated numerical separator standard.

This approach is in line with the guidance of the [International Bureau of Weights and Measures Service](#).

Figure 1 – BMJ Best Practice Numeral Style

5-digit numerals: 10,000

4-digit numerals: 1000

numerals < 1: 0.25

Our full website and application terms and conditions can be found here: [Website Terms and Conditions](#).

Contact us

+ 44 (0) 207 111 1105

support@bmj.com

BMJ

BMA House

Tavistock Square

London

WC1H 9JR

UK

Contributors:

// Authors:

Kul Aggarwal, MD, MRCP, FACC

Professor of Clinical Medicine
University of Missouri, Columbia, MO

DISCLOSURES: KA declares that he has no competing interests.

Albert K. Chan, MD

Assistant Professor of Clinical Medicine
University of Missouri, Columbia, MO

DISCLOSURES: AKC declares that he has no competing interests.

// Acknowledgements:

Professor Kul Aggarwal and Dr Albert K Chan would like to gratefully acknowledge Dr Nipun Arora and Lokesh Tejwani, previous contributors to this topic. NA declares that he has no competing interests.

// Peer Reviewers:

Debabrata Mukherjee, MD

Gill Foundation Professor of Interventional Cardiology
Director of Cardiac Catheterization Laboratories, Gill Heart Institute, Division of Cardiovascular Medicine,
University of Kentucky, Lexington, KY

DISCLOSURES: DM declares that he has no competing interests.

Syed Wamique Yusuf, MD, MRCPI, FACC

Associate Professor
University of Texas MD Anderson Cancer Center, Department of Cardiology, Houston, TX

DISCLOSURES: SWY declares that he has no competing interests.

Andrew Turley, MB ChB

Cardiology Specialist Registrar
The James Cook University Hospital, Middlesbrough, UK

DISCLOSURES: AT declares that he has no competing interests.